Vhl Disease Associated Cancers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Jaleh fallahInternational kidney cancer symposiumDivision of ophthalmologyNational institutes of healthKidney cancer symposiumNational institutesRenal cell carcinomaVon hippel lindauVhl disease associated cancers